Published in Gene Therapy Weekly, February 24th, 1997
DLK is a member of a family of proteins which appear to have the ability to maintain cells in an undifferentiated state. The patent, which is assigned to the U.S. National Institutes of Health (NIH), is exclusively licensed to ImClone for stem cell and gene therapy applications.
The DLK protein and gene were discovered by Dr. Jorge Laborda, U.S. Food and Drug Administration (FDA). In October 1996, ImClone signed an exclusive, worldwide patent license with the NIH for stem cell and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.